C osts of cardiovascular drugs in Canada increased by more than 200% from 1996 to 2006. The use of angiotensin-receptor blockers grew at an especially high rate, rising by more than 4000% during that period. 1 Such an increase in the use of these agents is not strongly supported by evidence. 1 Although angiotensinreceptor blockers were effective in reducing mortality and morbidity associated with hypertension in one large trial, patients in the control group were not given an angiotensin-converting-enzyme (ACE) inhib itor. 2 Instead, they received atenolol, a β-blocker, a drug class whose use is increasingly being questioned in the management of high blood pressure uncomplicated by prior myocardial infarction, heart failure or tachy arrhythmia. 3, 4 Although angiotensin-receptor blockers are not associated with dry cough, a side effect reported by 5%-35% of patients taking ACE inhibitors, 5 this side effect is benign and fully reversible once the drug is stopped. Meta-analyses that included several randomized trials failed to show superiority of angiotensin-receptor blockers over ACE inhibitors for the treatment of hypertension, 6 heart failure 7 or the secondary prevention of coronary artery disease. 8 Innovative policies are needed to offset the ever-increasing costs of cardiovascular drugs in Canada. Currently, British Columbia is the only province that restricts access to angio tensinreceptor blockers. Given that these agents can safely be substituted by ACE inhibitors and still yield similar clinical outcomes, [6] [7] [8] restricting their access is expected to lead to cost savings without adversely affecting patient heath. We estimated the potential cost savings that might have been achieved had access to angiotensin-receptor blockers been restricted in Canada in 2006.
Methods

Study design
We conducted a cost-minimization economic analysis using a decision-tree model with province-level data on drug costs obtained from IMS Health Canada's Canadian CompuScript Audit Database. 1, 9 We built the model to perform our base-case analysis and sensitivity analyses over a
The potential economic impact of restricted access to angiotensin-receptor blockers Background: The use of angiotensin-receptor blockers increased by more than 4000% in Canada from 1996 to 2006. The benefit of these medications over angiotensin-convertingenzyme (ACE) inhibitors has not been proven aside from a reduction in dry cough. We estimated the potential cost savings that might have been achieved had access to angiotensinreceptor blockers been restricted.
Methods:
We performed a cost-minimization analysis with a decision-tree model using a societal perspective over a one-year period. Sources of data for model parameters includ ed IMS Health Canada data collected from onethird of all retail pharmacies for the cost and use of angiotensin-receptor blockers and ACE inhib itors in each province, as well as published studies for administrative costs and in cidence of dry cough. We used Monte Carlo simulations with 10 000 iterations to test the impact of several model parameters (e.g., drug prices, administrative costs and the incidence of dry cough). All data are in 2006 Can adian dollars. one-year period from a societal perspective ( Figure 1 ). Using the model, we compared direct health care costs in 2006 associated with two scenarios. The first scenario reflected the status quo of no restriction on the use of angiotensin-receptor blockers across Canada except in Brit ish Columbia. Actual 2006 data on costs were used.
Results
The second scenario tested the economic outcomes had a policy restricting the use of angiotensin-receptor blockers been implemented on Jan. 1, 2006 . We assumed that patients would receive treatment for one year. Under this policy, those already taking an angiotensin-receptor blocker or an ACE inhibitor would continue taking their existing therapy for the duration of the year. New patients considered for angiotensinmodifying treatment would be prescribed an ACE inhibitor first. We assumed that constraints on the use of angio tensin-receptor blockers would be more acceptable if the initially prescribed ACE inhibitor was not one that required multiple doses per day (e.g., captopril and enalapril). Patients already receiving these ACE inhibitors, however, would not be switched to another regimen. New patients prescribed any of the other ACE inhibitors would be switched to an angiotensin-receptor blocker after the first month if dry cough developed.
In modelling the restriction-policy arm, we used province-level data on market share for the ACE inhibitors that did not require multiple daily doses. Using these data to determine the proportion of patients prescribed each ACE inhibitor as first-line treatment would tend to favour newer, and possibly more effective, agents. 10 Finally, we assumed no restriction on angiotensin-receptor blockers within the class, with prescription rates of each agent based on provincial market share data for each drug in 2006.
Estimation of drug use and costs
Actual 2006 data on market shares and monthly costs for angiotensin-receptor blockers and ACE inhibitors were extracted from IMS Health Canada's Canadian CompuScript Audit Database for all provinces. This database uses audits at the retail pharmacy level to estimate the number and value of prescriptions dispensed through out Canada. Pharmacy outlets are stratified by re gion, type of retailer (independent or chain store) and size. Sample stores selected for audit represent about one-third of all retail pharmacies. Data for the audit are collected monthly by electronic means. After passing through various qualitycontrol verifications, the sample data are projected to the total group of pharmacies in each region; regional totals are then summed to provide a national estimate. The data collected can be used to determine product use by drug class as well as costs of the prescriptions as dispensed (including all mark-ups and pharmacists' fees).
For our study, we included data from Jan. 1, 2005, to Dec. 31, 2006. IMS Health Canada does not measure population-wide, patient-specific data. Since we could not obtain patient-level costs, we extrapolated monthly average dispensation costs at a provincial level from the IMS Health Canada database.
Switching from an ACE inhibitor to an angiotensin-receptor blocker was assumed to be associated with additional physician consultation fees and administrative costs. We extracted physician fees from each province's physician's manual on fee schedules. [11] [12] [13] [14] [15] [16] [17] [18] Administrative fees were based on those associated with reference pricing for ACE inhibitors in British Columbia as reported by Schneeweiss and colleagues 19 and were actualized to 2006 values using the Consumer Price Index for health care in 2006. To be conservative, in the Quebec model, we assumed that a pharmacist consultation fee would be re quired in addition to a physician fee.
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Estimation of drug effectiveness and side effects We assumed that selected ACE inhibitors and angiotensin-receptor blockers were of equivalent effectiveness within their respective drug classes for every possible indication. [6] [7] [8] This assumption was fundamental for the validity of our costminimization analysis.
From the available Canadian pharmacoepidemiologic data, we determined that 9.2% of patients prescribed an ACE inhibitor later switched to an angiotensin-receptor blocker within one year. We used this switch rate as the base-case value for the incidence of dry cough, acknowledging that switches might not be all related to this side effect of ACE inhibitor use. Angiotensin-receptor blockers were assumed to be free of side effects.
Statistical analysis
Because of variability in drug costs and utilization rates between provinces, we analyzed data for each province separately except those for Newfoundland and Labrador and for Prince Edward Island, which we analyzed together because of how they were provided by IMS Health Canada. The savings of the restriction policy are presented in total absolute savings and relative savings. Given the short-term perspective of our analysis, no discounting was applied. To test the robustness of the base-case analysis, we used Monte Carlo simulations with 10 000 iterations to estimate the impact of several model parameters. The parameters included drug costs, incidence of dry cough, new-to-existing patient ratios, number of patients affected by the restriction policy and administrative costs associated with switching from an ACE inhibitor to an angio tensin-receptor blocker.
One-way sensitivity analyses were performed to assess the impact of each model parameter on cost savings. In a final sensitivity analysis, we examined the impact of British Columbia's drug utilization ratios for new and existing patients in 2006 on each provincial model. We also applied data on British Columbia's market shares for ACE inhibitors and angiotensin-receptor blockers to each provincial model. Table 1 tions targeting the renin-angiotensin system were for an angiotensin-receptor blocker, and we assumed that these patients would continue to take their angiotensin-receptor blocker in 2006. We assumed that an administrative fee of $7.83 would be applied for the evaluation of each authorization demand to switch to an angiotensin-receptor blocker as a result of dry cough from ACE inhibitor use.
Results
Parameter estimates
Actual drug use and costs
Actual utilization rates and costs per month for each ACE inhibitor and angiotensin-receptor blocker in 2006 are shown in Table 2 . The most frequently dispensed ACE inhibitors were ramipril and lisinopril. Of the angiotensin-receptor blockers, the most frequently prescribed agents were valsartan and irbesartan.
Potential cost savings with restricted access
Results of the base-case model show that a policy of restricted access to angiotensin-receptor blockers might have saved $77.1 million overall in 2006 (Table 3) ; this value represents 5.6% of the total expenditures for angiotensin-receptor blockers and ACE inhibitors. Results also show potential cost savings in every province. Table 4 shows the results of the Monte Carlo simulations for absolute and relative potential savings by province. The total absolute savings (mean $58.3 million, 95% confidence interval $29.3 million to $90.8 million) support the results of the base-case analysis. Every simulation showed a cost savings in every province.
Sensitivity analyses
In the one-way sensitivity analyses of the impact of model parameters on cost savings, only a handful of highly unlikely circumstances would have changed the direction of the results: the incidence of dry cough or the rate of switching from an ACE inhibitor to an angiotensinreceptor blocker would have to surpass 58%; the percentage of patients already taking an angio tensin-receptor blocker would have to exceed 43% (reducing the proportion of new patients affected by the restriction policy to 11%); or the administrative fees associated with switching to an angiotensin-receptor blocker would have to be more than $1738 per prescription reviewed.
In one of the sensitivity analyses, we tested the effect of generic versions of patented drugs on potential savings. Because the most frequenly prescribed medications will be off patent by 2011, 21 we analyzed the effect of the restriction policy in a 2012 setting. We assumed that the price of patented drugs in 2006 that were going off patent before Jan. 1, 2012 (lisinopril, enalapril, fosinopril, eprosartan, ramipril, candesartan, irbesartan and valsartan), would be halved (based on recent legislation in Ontario limiting generic drug reimbursement to 50% of the cost of the brand name drug). All other parameters were kept at their base-case values. This analysis showed a cost saving in every province and a total potential saving across Canada of $19.9 million (2.3% relative savings compared to the total cost of ACE inhibitors and angiotensin-receptor blockers).
In the sensitivity analysis of the impact of British Columbia's existing-to-new patient ratios and market shares on each provincial model, the results were similar to those of the base-case analysis, with a potential savings of $85 million.
Interpretation
Our analyses showed that, had a policy restricting access to angiotensin-receptor blockers been implemented in Canada in 2006, the cost savings that year might have been $77.1 million, likely without any adverse effect on health outcomes. A restrictive policy is currently in place in the province of British Columbia. In one of our sensitivity analyses, in which we used the same market shares observed in British Columbia in 2006, we found that the potential savings of $85 million was similar to the savings projected in the base-case analysis. Administrators of drug benefit plans need to consider carefully the restriction of specific drugs, let alone an entire class, especially in the absence of an effective alternative. In Quebec and Ontario, restricted access to clopidogrel led to underuse and increased mortality. 22, 23 However, in the case of angiotensin-receptor blockers, restricted access can result in substantial savings without leading to underuse or adverse clinical outcomes. In Sweden, reimbursement restrictions for angiotensin-receptor blockers were implemented in 2008. Since then, the proportion of the Swedish population dispensed an angiotensin-receptor blocker de creased by 24% in favour of other drugs and led to a decrease of close to 5% in total drug expenditures. 24 Other simple ways to save money have been proposed, such as switching from a thiazide diuretic plus either an ACE inhibitor or an angiotensin-receptor blocker to a single combination product. Such a strategy could potentially save up to $45 million, again without any adverse effect on cardiovascular health and likely with a favourable impact on drug adherence. 25 Given a future of increasing economic uncertainty complicated by a demographic shift to an older population with a relatively shrinking tax base, measures are needed to deal with the rising health care costs. 26 Policies can neither be draconian nor take a one-size-fits-all approach. Patient well-being must always come first. Cost-sharing strat egies such as co-payments or caps are a less satisfactory solution to the increasing costs of cardiovascular medications, because they shift the financial burden to patients and may lead to underuse and adverse clinical outcomes. 27 We believe that, where treatment choice exists, favouring the least expensive medication over others of comparable effectiveness is one way to address future economic challenges without creating social disparities.
Limitations
Our study has limitations. First, we did not assess clinical outcomes because we were unable to obtain patient-level information. The assumption of equivalent outcomes with ACE inhibitors and angio tensin-receptor blockers may not be true in Canada, although this is extremely unlikely based on the bulk of evidence. In addition, we considered that all selected drugs were equivalent for every possible indication; however, there is still debate on the actual equivalence of these drugs.
Second, we considered only direct medical costs despite the societal perspective of our analysis. Costs not related to health care are likely negligible compared with the overall economic benefits of the policy.
Third, although side effects other than dry cough are known to be associated with ACE inhibitors, 28 we limited our analysis to dry cough. Finally, the short timeline of our base-case analysis ignores the effect of future generic and cheaper angiotensin-receptor blockers. However, as seen in our projected sensitivity analysis of the effect of brand name drugs going off patent in 2012, the policy of restricted access would still result in cost savings, although to a lesser degree ($19.9 million v. $77.1 million). 
